x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

Global Regions ( XML Feed )
United States ( XML Feed )

Apr 5, 2016 9:19 EST

Carmolex, Inc.: Early stage drug prospect discovery Services for big pharma and academic research initiatives

iCrowdNewswire - Apr 5, 2016

Carmolex, Inc.

Pittsburgh, PA 15219, US
Biotechnology
www.carmolex.com

Carmolex’s Leading Edge “Platform for Rational Drug Discovery” presents a “golden” therapeutic opportunity for bio-pharma clients, visionary investors and philanthropists

Carmolex provides a unique entry-level bio-discovery opportunity for those wishing to participate in the exciting and highly rewarding world of bio-tech. Far beyond the usual deals and 5X return on investment advertised by others Carmolex’s world-class scientists, leading edge software, and special chemistry deliver superior “starting points” with more than a 20 fold advantage over traditional pharmaceutical drug discovery approaches. Already having developed an in-house library of 400 million original molecules and with the value of its capabilities independently recognized by 4 scientific Grants in both the USA and Europe, Carmolex is a ‘diamond in the rough.’

With a risk adjusted, net present value of over $60 million, Carmolex is now beginning to commercialize its very efficient drug discovery Services and poised to further develop an internal pipeline of “hot” disease related treatment targets. On the shoulders of over $6 million in R&D funding, it is projected that within two years strategic partnerships with large pharma could result in up-front payments, per individual project, in the range of $25 million. Beyond that, upon FDA approvals, royalty agreements that could exceed hundreds of millions for years to come are possible.

Carmolex is important because big pharma is finding it difficult to refill its new drug pipelines as more of their billion dollar block buster patents expire. In today’s much more challenging business and scientific environment, Carmolex’s rational, highly targeted approach is key because it’s designed to deliver “personalized medicine” solutions. Carmolex provides those who are visionary with the opportunity to both profit and make life changing differences for all of us who will eventually be faced by cancer, infection, respiratory problems, allergy, arthritis, dementia and other diseases. Carmolex is prepared to offer 15% of its stock for $3 million.

Products / Services

Early stage drug prospect discovery Services for big pharma and academic research initiatives

Carmolex’s fee-for-service platform uses leading edge know-how, computational software and special chemistry to deliver its clients with superior starting points for today’s much more challenging disease related targets. Services include:

• Design of compounds for targets based on structural biology information using our InstantDockTM technology;
• Screening support;
• Synthesis of multiple HIT compounds per scaffold based on InstantChemTM;
Delivery of small molecular weight HITs for targets (e.g., protein-protein interactions, allostery, and selectivity in protein families), in 20mg quantities with >93% purity;
• HITs validation using co-crystal structure analysis and biochemical assays; and
• HITs to leads selectivity optimization.

Early stage drug prospect discovery Services for big pharma and academic research initiatives

Carmolex’s fee-for-service platform uses leading edge know-how, computational software and special chemistry to deliver its clients with superior starting points for today’s much more challenging disease related targets. Services include:

• Design of compounds for targets based on structural biology information using our InstantDockTM technology;
• Screening support;
• Synthesis of multiple HIT compounds per scaffold based on InstantChemTM;
Delivery of small molecular weight HITs for targets (e.g., protein-protein interactions, allostery, and selectivity in protein families), in 20mg quantities with >93% purity;
• HITs validation using co-crystal structure analysis and biochemical assays; and
• HITs to leads selectivity optimization.

Early stage drug prospect discovery Services for big pharma and academic research initiatives

Carmolex’s fee-for-service platform uses leading edge know-how, computational software and special chemistry to deliver its clients with superior starting points for today’s much more challenging disease related targets. Services include:

• Design of compounds for targets based on structural biology information using our InstantDockTM technology;
• Screening support;
• Synthesis of multiple HIT compounds per scaffold based on InstantChemTM;
Delivery of small molecular weight HITs for targets (e.g., protein-protein interactions, allostery, and selectivity in protein families), in 20mg quantities with >93% purity;
• HITs validation using co-crystal structure analysis and biochemical assays; and
• HITs to leads selectivity optimization.

Early stage drug prospect discovery Services for big pharma and academic research initiatives

Carmolex’s fee-for-service platform uses leading edge know-how, computational software and special chemistry to deliver its clients with superior starting points for today’s much more challenging disease related targets. Services include:

• Design of compounds for targets based on structural biology information using our InstantDockTM technology;
• Screening support;
• Synthesis of multiple HIT compounds per scaffold based on InstantChemTM;
Delivery of small molecular weight HITs for targets (e.g., protein-protein interactions, allostery, and selectivity in protein families), in 20mg quantities with >93% purity;
• HITs validation using co-crystal structure analysis and biochemical assays; and
• HITs to leads selectivity optimization.

Management

Chief Executive Officer
Rafael Vélez, MD

Rafael Vélez, MDRafael Vélez, MD, CEO and Co-Founder of Carmolex, is a physician, anesthesiologist, and entrepreneur. He was the first to fund Carmolex and is known for his vision and team-building skills. He has also been an early investor in other start-ups, such as: Brainstage, Inc., a Pittsburgh Life Sciences Greenhouse portfolio company that acquires, develops, and commercializes drug development and healthcare technologies through specialized operating companies; and Cima Software Corp., which focuses on cloud-based solutions and management of unstructured documents, with over 300 clients including American Airlines, Kellogg’s, and Price Waterhouse.

Chief Science/Scientist
Alexander Dömling, PhD

Alexander Dömling, PhDAlexander Dömling, PhD, Chief Scientific Officer and Co-Founder of Carmolex, is Chair of Drug Design, University of Groningen, and is a world authority in multi-component reaction chemistry with valuable industry and academic experience in the field of drug discovery/development and medicinal chemistry and more than 100 peer reviewed papers. He leads the chemistry development and quality control for customers.

Consulting Science/Scientist
Carlos J. Camacho, PhD

Carlos J. Camacho, PhDCarlos J. Camacho, PhD, Co-Founder of Carmolex, is Professor of Computational and Systems Biology, University of Pittsburgh, and is an expert in protein-protein interactions. In more than 60 publications, he revealed the role of desolvation and anchor residues in recognition, developing the first docking program “ClusPro” (licensed to Schrodinger LLC), and novel interactive technologies (AnchorQuery, PocketQuery, ANCHOR and ZINCPharmer) for leveraging protein structures as small-molecule inhibitor starting points.

Group Leader/Lead Manager
Kareem Khoury, PhD

Kareem Khoury, PhD, Director of Drug Design, leads Carmolex’s client delivery team. Kareem holds a PhD in Medicinal Chemistry from the University of Pittsburgh.

Director
Kenneth R. Melani, MD

Kenneth R. Melani, MD, served as President and Chief Executive Officer of Highmark Inc. from January 2003 to March 2012 and was responsible for day-to-day business operations, and currently is the Chairman of the Board of LifeWatch AG, a leading technology and solutions provider.

Consulting Technology/Technologist
David Koes, PhD

David Koes, PhD. in Computer Science, is an expert in high performance computing, systems building, optimization, and algorithms; with over 6 years of industry experience in software development. David obtained his PhD from Carnegie Mellon University and is currently a professor at the University of Pittsburgh.

Contact Information:

Chief Executive Officer
Rafael Vélez, MD

Chief Science/Scientist
Alexander Dömling, PhD

Consulting Science/Scientist
Carlos J. Camacho, PhD

Group Leader/Lead Manager
Kareem Khoury, PhD

Director
Kenneth R. Melani, MD

Consulting Technology/Technologist
David Koes, PhD

View Related News >
support